Fig. 2From: CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapyPFS (A) and OS (B) in patients with high or low baseline NLR. PFS: median follow-up was 54.7 months in patients with low NLR, and was not available for those with high NLR. OS: median follow-up was 51.8 months in patients with low NLR, and 75.7 months for those with high NLRBack to article page